Abstract:Canavan disease is a severe progressive neurodegenerative disorder that is characterized by swelling and spongy degeneration of brain white matter. The disease is genetically linked to polymorphisms in the aspartoacylase ( ASPA ) gene, including the substitution C152W. ASPA C152W is associated with greatly reduced protein levels in cells, yet biophysical experiments suggest a wild-type like thermal stability. Here, we examine the stability and degradation pathway of ASPA C152W. When we expressed ASPA C152W in Saccharomyces cerevisiae , we found a decreased steady state compared to wild-type ASPA as a result of increased proteasomal degradation. However, molecular dynamics simulations of ASPA C152W did not substantially deviate from wild-type ASPA, indicating that the native state is structurally preserved. Instead, we suggest that the C152W substitution prevents ASPA from reaching its stable native conformation, presumably by impacting on de novo folding. Systematic mapping of the protein quality control components acting on misfolded and aggregation-prone species of C152W, revealed that the degradation is highly dependent on the molecular chaperone Hsp70, its co-chaperone Hsp110 as well as several quality control E3 ubiquitin-protein ligases, including Ubr1. In human cells, ASPA C152W displayed increased proteasomal turnover that was similarly dependent on Hsp70 and Hsp110. We propose that Hsp110 is a potential therapeutic target for misfolding ASPA variants that trigger Canavan disease due to excessive degradation. ### Competing Interest Statement The authors have declared no competing interest.

Human induced pluripotent stem cell line (SDQLCHi064-A) derived from a patient with Canavan disease carrying c.556_559dup GTTC and c.919delA mutations in the ASPA gene

Generation of an Induced Pluripotent Stem Cell Line from a Brugada Syndrome Patient Carrying SCN5A/c.3118G>C Mutation

Cell‐Based Therapy for Canavan Disease Using Human iPSC‐Derived NPCs and OPCs

Generation of Induced Pluripotent Stem Cell Line (Zzui007-A) from a 52-Year-old Patient with a Novel CHCHD2 Gene Mutation in Parkinson's Disease.

Therapeutic development for Canavan disease using patient iPSCs introduced with the wild-type ASPA gene

Establishment of Induced Pluripotent Stem Cell Line (Zzui010-A) from an Alzheimer's Disease Patient Carrying an APP Gene Mutation.

An induced pluripotent stem cell line (EHTJUi004-A) generated from a neonate with c.4683_4684delCT:p.Leu1563fs mutation in the gene <i>DSP</i> causing Familial Arrhythmogenic Right Ventricular Dysplasia (ARVD)

Clinical and Aspartoacylase Gene Mutation Analysis of Canavan Disease in a Child

Analysis of Aspartoacylase Gene Mutations in One Chinese Family with Canavan Disease

[Genetic analysis and prenatal diagnosis for a Chinese pedigree affected with Canavan disease]

Generation and characterization of PBMCs-derived human induced pluripotent stem cell (iPSC) line SDQLCHi055-A from a patient with NEDSDV carrying a heterozygote mutation in the CTNNB1 gene

Clinical Characteristics and Induced Pluripotent Stem Cells (ipscs) Disease Model of Harel-Yoon Syndrome Caused by Compound Heterozygous ATAD3A Variants

Evolutionarily conserved chaperone-mediated proteasomal degradation of a disease-linked aspartoacylase variant

Establishment of a human induced pluripotent stem cell line(SDQLCHi059-A)from a patient with congenital disorder of glycosylation carrying heterozygous mutation in MPI gene

Homozygous Paternally Inherited ASPA Variant in a Patient with Canavan Disease

Two patients with Canavan disease and structural modeling of a novel mutation

Two novel missense mutations in the aspartoacylase gene in a Chinese patient with congenital Canavan disease.

Generation of a human induced pluripotent stem cell line (SDUBMSi001-A) from a hereditary spastic paraplegia patient carrying kif1a c.773C>T missense mutation.

A novel Aspartoacylase (ASPA) Gene Mutation in Canavan Disease

New T530C mutation in the aspartoacylase gene caused Canavan disease with no correlation between severity and N-acetylaspartate excretion

Clinically Distinct Phenotypes of Canavan Disease Correlate with Residual Aspartoacylase Enzyme Activity